For those of us with bone metastases Zometa® is a drug many of us receive to help maintain bone being ravaged by both cancer and treatment. The Federal Drug Administration (FDA) this week approved Xvega®, a new drug developed to delay the onset of skeletal related events (SRE), such as fracture or vertebral compression, that cause pain and require treatment either by radiation or surgery. In studies comparing Xgeva to Zometa, Xgeva showed that SRE were delayed a number of months longer than Zometa.
bone mets: FDA approves Xgeva
Posted on November 20, 2010